IBM's Quantum Subsidy Finally Lands — and Traders Head for the Exits

IBM closed at EUR 201.90, down 2.5%, after its Anderon LLC unit finalized a $1B CHIPS award; weak software deals cut 2026 growth guidance to 4-5%.

IBM shares closed Friday at EUR 201.90, down 2.5%, after the company's Anderon LLC subsidiary locked in a USD 1 billion award under the CHIPS and Science Act with the US Department of Commerce. The midweek finalization bankrolled a build-out of quantum wafer manufacturing, but the confirmation itself became the trigger for selling rather than buying.

That is because the market had already been pricing in Washington's backing since May. With the subsidy anticipated for months, the official seal gave short-term traders and institutions a textbook "sell the news" moment. The money is earmarked for research and production of 300-millimeter quantum wafers in New York State.

A softer core is doing the real damage

Underneath the headline move sits a more stubborn problem: corporate customers are still guarding their technology budgets, and IBM's most profitable franchises are feeling it. Delays in closing large enterprise software deals have pushed the company's leadership to trim its full-year revenue growth target to 4% to 5%. Management has said several postponed customer orders should land in the third quarter.

The summer already showed the strain. In the second quarter of 2026, IBM missed expectations with adjusted earnings per share of USD 2.93 on revenue of USD 17.16 billion. Transaction processing and software remain the segments investors watch most closely, since the valuation case rests on high-margin software and cloud rather than the steady but slower infrastructure and services business.

How quickly those stalled contracts convert into booked revenue is now the central question. If the pipeline slips further, the existing 2026 guidance comes under real pressure.

Quantum wins keep the bull case alive

Against that backdrop, IBM has hardly stood still on the technology front. Early September brought news of a 25-fold throughput gain in quantum computing. The company also teamed up with Lockheed Martin on a joint innovation center at ETH Zurich, where the first IBM Quantum System Two in Switzerland is slated to go live by the end of 2026. Roughly two weeks ago, IBM joined Microsoft in backing a bill to promote the US quantum industry.

Commercial traction is building elsewhere too. IBM expanded its cooperation with Turkey's Kredi Kay?t Bürosu, whose platform runs on mainframe and watsonx technologies and is designed to process more than 8.5 billion transactions a year. The company also launched an AI Lighthouse Council for users of SAP systems to build out AI agent structures together.

Analysts have taken note. Weiss Ratings upgraded the stock to "Buy (B-)" from "Hold (C+)" on September 11, and several institutional investors added to their positions during the second quarter of 2026 — a sign that longer-horizon money still sees value.

Insider selling and a bruised chart cut the other way

Not everyone is convinced. The bearish camp points to the balance sheet's persistent drag and muted growth momentum. The stock is down 22% year to date, a reflection of lingering doubt about the turnaround. Fears of another cut to the 2026 targets have not faded, especially as the hoped-for pace of monetizing new AI solutions trails optimistic market expectations.

A mandatory disclosure from late August added to the caution: Senior Vice President Robert David Thomas sold 25,000 shares on August 26 at an average price of USD 230.32, generating proceeds of USD 5.758 million. Insider sales during a period of weaker guidance rarely reassure the broader investor base.

October 21 is the next reckoning

For now, the shares are holding their recent level, keeping the possibility of stabilization intact. But another round of headlines about stalled software contracts could send the stock back to test its yearly lows.

The next hard test of whether the current valuation can stand is already on the calendar. IBM will publish its official interim report for the past quarter on October 21, 2026. Only then will it become clear whether the delayed software deals have finally materialized — or whether management must lower its 2026 outlook once again.